Celyad Oncology SA Logo

Celyad Oncology SA

Clinical-stage biotech developing CAR T therapies for solid and blood cancers.

CYAD | BR

Overview

Corporate Details

ISIN(s):
BE0974260896 (+2 more)
LEI:
549300ORR0M8XF56OI64
Country:
Belgium
Address:
RUE ANDRE DUMONT 9, 1435 MONT-SAINT-GUIBERT
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Celyad Oncology SA is a clinical-stage biotechnology company that specializes in the discovery and development of Chimeric Antigen Receptor T-cell (CAR T) therapies for cancer treatment. The company focuses on pioneering advanced technologies to create a pipeline of both allogeneic (off-the-shelf) and autologous (patient-derived) CAR T-cell candidates. Celyad's differentiated strategy aims to broaden the range of treatable cancer indications, including hematological malignancies and solid tumors, while addressing the primary limitations of existing CAR T-cell therapies.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-04 00:00
Declaration of Voting Results & Voting Rights Announcements
20250904_PR_Double-voting-rights.ENG_Website.pdf
English 154.5 KB
2025-09-04 00:00
Declaration of Voting Results & Voting Rights Announcements
20250904_PR_Double-droit-de-vote.FR_Website.pdf
French 91.2 KB
2025-08-26 08:30
Regulatory News Service
20250826_PR_R&D discontinuation ENG.FINAL.clean.pdf
English 176.9 KB
2025-08-26 08:30
Regulatory News Service
20250826_PR_Arret R&D FR.FINAL.pdf
French 162.6 KB
2025-08-13 00:00
Major Shareholding Notification
20250913_PR_Fortress Transparency Notification ENG.Final.pdf
English 238.9 KB
2025-08-13 00:00
Major Shareholding Notification
20250913_PR_Fortress Transparency Notification FR.Final.pdf
French 224.1 KB
2025-08-07 00:00
Declaration of Voting Results & Voting Rights Announcements
20250807 PR_Total Number of Voting Rights and Shares_ENG.3.pdf
English 106.6 KB
2025-08-07 00:00
Declaration of Voting Results & Voting Rights Announcements
20250807 PR_Total Number of Voting Rights and Shares_FR.2.pdf
French 110.9 KB
2025-08-07 00:00
Declaration of Voting Results & Voting Rights Announcements
20250807 PR_Total Number of Voting Rights and Shares_ENG.3.pdf
English 106.6 KB
2025-08-07 00:00
Declaration of Voting Results & Voting Rights Announcements
20250807 PR_Total Number of Voting Rights and Shares_FR.2.pdf
French 110.9 KB
2025-08-05 00:00
Post-Annual General Meeting Information
PV Notaire.5août2025.signed.pdf
French 334.3 KB
2025-08-05 00:00
Audit Report / Information
CELYAD_ Rapport de Commissaire - Augm de K 1 MEUR_VDEF_SIGNED_280725.pdf
French 150.8 KB
2025-08-05 00:00
Share Issue/Capital Change
FR_Celyad_Rapport Special du CA_PIPE2025_23juillet2025.FE.pdf
French 2.6 MB
2025-08-05 00:00
Share Issue/Capital Change
20250724_CYAD-PR-PIPE-ENG.2.pdf
English 113.4 KB
2025-08-05 00:00
Share Issue/Capital Change
20250724_CYAD-PR-PIPE-FR.2.pdf
French 86.4 KB

Automate Your Workflow. Get a real-time feed of all Celyad Oncology SA filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Celyad Oncology SA via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-11-28 Kane Matthew Board Other 1,035,714 279,642.78 EUR
2024-11-26 Piscitelli Dominic Board Other 10,000 2,700.00 EUR
2024-11-25 Iserentant Hannes Executive member Other 30,000 8,100.00 EUR
2024-11-22 Phan An Executive member Other 30,000 8,100.00 EUR
2024-11-06 Goblet Serge Board Other 10,000 2,700.00 EUR
2024-11-05 Udier Blagovic Marina Board Other 10,000 2,700.00 EUR

Peer Companies

Company Country Ticker View
Developing novel cancer immunotherapies, including peptide vaccines and iPS-NKT cell therapies.
Japan 4594
Brilliant Future AB Logo
A data-driven survey platform to measure and improve employee & customer experiences.
Sweden BRILL
b-style holdings,Inc. Logo
Offers flexible staffing for homemakers and specialized recruitment for skilled professionals.
Japan 302A
BTS Group Logo
Helps organizations execute strategy via experiential learning for leadership and sales teams.
Sweden BTS
B.U Technology Logo
Commercializes university research via IP management, licensing, and new venture creation.
South Korea 230980
Advancing high-grade copper and precious metal projects from discovery to production.
Canada N/A
Cantargia Logo
Develops antibody treatments targeting IL1RAP for cancer and autoimmune/inflammatory diseases.
Sweden CANTA
Captor Therapeutics S.A. Logo
Developing TPD therapeutics for oncology and autoimmune diseases with its Optigrade™ platform.
Poland CTX
Offers one-stop BPO, CRM, and staffing for admin, manufacturing, and logistics.
Japan 6070
Carna Biosciences, Inc. Logo
Develops kinase inhibitor drugs for oncology/autoimmune diseases & offers discovery support services.
Japan 4572

Talk to a Data Expert

Have a question? We'll get back to you promptly.